Mutual of America Capital Management LLC Cuts Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Mutual of America Capital Management LLC reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,757 shares of the company’s stock after selling 3,813 shares during the period. Mutual of America Capital Management LLC owned 0.18% of Amphastar Pharmaceuticals worth $5,428,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $28,000. Ronald Blue Trust Inc. grew its position in shares of Amphastar Pharmaceuticals by 821.5% in the third quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock valued at $55,000 after purchasing an additional 1,068 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Amphastar Pharmaceuticals by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after purchasing an additional 628 shares in the last quarter. Point72 Middle East FZE purchased a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $50,000. Finally, Covestor Ltd grew its position in shares of Amphastar Pharmaceuticals by 859.0% in the third quarter. Covestor Ltd now owns 1,966 shares of the company’s stock valued at $90,000 after purchasing an additional 1,761 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the transaction, the director now directly owns 21,326 shares in the company, valued at $1,006,160.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Floyd F. Petersen sold 500 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the sale, the director now directly owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael A. Zasloff sold 12,500 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The disclosure for this sale can be found here. Insiders have sold 14,000 shares of company stock worth $660,860 over the last ninety days. Corporate insiders own 28.40% of the company’s stock.

Amphastar Pharmaceuticals Stock Down 1.3 %

NASDAQ:AMPH opened at $39.62 on Monday. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The stock’s fifty day moving average is $47.31 and its two-hundred day moving average is $51.39. Amphastar Pharmaceuticals, Inc. has a 52 week low of $35.62 and a 52 week high of $67.66. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of 15.36, a price-to-earnings-growth ratio of 0.94 and a beta of 0.84.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. The firm had revenue of $178.11 million for the quarter, compared to analyst estimates of $174.90 million. Research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on AMPH. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. began coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.